SEP 11, 2015 10:08 PM PDT

AML Answer

WRITTEN BY: Ilene Schneider
A protein domain may be critical to helping patients fighting acute myeloid leukemia (AML) avoid a relapse. Researchers at Rice University, working with colleagues at Baylor College of Medicine and the University of Texas MD Anderson Cancer Center, have developed a small molecule that could deliver a “one-two punch” to proteins that resist chemotherapy in patients with AML.

Small molecule helps patients fight acute myeloid leukemia.

Called STAT3, the protein interferes with chemotherapy by halting the death of cancerous cells and enabling them to grow. The molecule discovered at Rice finds and then attacks a previously unknown binding site on STAT3, disrupting its disease-promoting properties. The work led by Rice chemist Zachary Ball, Baylor pediatrician Michele Redell and MD Anderson oncologist David Tweardy appears in the journal Angewandte Chemie and is reported in Bioscience Technology

An earlier discovery by Ball’s lab led to the discovery and exploitation of this new drug target. That discovery enabled researchers to identify, on a molecular level, the target of action for drug molecules by using rhodium-based inorganic complexes. The complexes recognize specific folds in a protein chain and catalyze minute changes in those sequences, thus forming a “tag” for later analysis.

The STAT3 protein (“signal transducer and activator of transcription 3″) is a suspected culprit in the relapse of nearly 40 percent of children who have AML. The new proximity-driven rhodium(II) catalyst known as MM-206 seeks and modifies an inhibitor-binding site on the protein and delivers the inhibitor, naphthalene sulfonamide, to the modified site.

According to Ball, “This is the confluence of two ideas we’ve been working on around what you can do with conjugates linked to rhodium.”

Redell, who is also part of the leukemia and lymphoma teams at Texas Children’s Hospital, added, “We know that increased activity of STAT3 in AML and other cancers helps the cancer cells survive chemotherapy, so any new strategy we can develop to stop that process could mean real benefit for our patients.”

Ball explained that STAT3 has been a target for scientists trying to shut down cancer cells, saying, ”STAT fits in the broad category of what are called ‘undruggable protein-protein interactions.’ There’s a large surface area with weak interactions for which we have typically failed to find good drugs.”

Prior research revolved around only one region of STAT3, its SH2 domain, with limited success. Ball added, “There’s no evidence people have tried to go after the coiled coil as a drug target. Our main advance, from a medicinal perspective, is that this compound also works in a mouse model. All the other compounds worked in cells, but in mice, they weren’t potent enough or stable enough. The discovery raises new questions about STAT3 biology and points the way to future anti-cancer approaches, including combination therapies of coiled-coil STAT3 inhibitors in tandem with other agents.”
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
APR 02, 2020
Cancer
APR 02, 2020
Diagnosing Cancer: SMOC2 and Thyroid Cancer
  Thyroid cancer is the most common of the endocrine cancers, with papillary thyroid carcinomas (PTCs) being the mo ...
MAR 31, 2020
Cancer
MAR 31, 2020
Ovarian cancer metastasis and CPT1A
Research published in the journal Molecular Cancer Research from collaborators at the University of Colorado C ...
MAY 02, 2020
Drug Discovery & Development
MAY 02, 2020
Glioblastoma Treatment Using Schizophrenic Drug Plus Radiation
A therapeutic used for the treatment of schizophrenia could be a gateway for targeting glioblastoma, one of the deadlies ...
MAY 16, 2020
Cancer
MAY 16, 2020
Red Blood Cells: More than just an Oxygen Delivery Service
The human body is a complex network of systems that often interact and affect each other. Recent work shows that red blo ...
MAY 21, 2020
Cancer
MAY 21, 2020
When is the best time to talk about end-of-life decisions with your teen who has cancer?
A study published recently in JAMA Network highlights the need for improved pediatric advanced care for adolescents with ...
JUN 01, 2020
Cancer
JUN 01, 2020
A New RNA in Fine-Tuned Signal Regulation
In a healthy cell, many complex networks work to make sure everything runs as it should. Some of these networks function ...
Loading Comments...